AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00265954 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: internet, in-person and internet+in-person
Description: All participants receive an 18 month behavioral weight loss program that meets weekly for the first 6 months and monthly for the next year.
Study NCT04207385 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: pharmacogenomics
Description: pharmacogenomics
Study NCT04207385 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: pharmacogenomics
Description: pharmacogenomics
Study NCT04207385 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: pharmacogenomics & therapeutic drug monitoring
Description: pharmacogenomics \& therapeutic drug monitoring
Study NCT04207385 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine
Description: Venlafaxine hydrochloride sustained-release capsules 75mg x 14 tablets x 1 case 75-225mg/morning
Study NCT04207385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Description: Venlafaxine hydrochloride sustained-release capsules 75mg x 14 tablets x 1 case 75-225mg/morning
Study NCT01491503 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levocetirizine
Description: Levocetirizine dihydrochloride 5mg. PO. Single dose.
Study NCT01491503 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: montelukast sodium
Description: Montelukast sodium 10mg. PO. Single dose.
Study NCT01491503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast & levocetirizine
Description: Montelukast sodium 10mg \& levocetirizine dihydrochloride 5mg PO. Single dose.
Study NCT03059654 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tracheostomy
Study NCT01427894 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maternal singing with Kangaroo Care
Description: Maternal singing with Kangaroo Care
Study NCT02700815 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Study NCT02700815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac
Study NCT02700815 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capsaicin
Study NCT02700815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin
Study NCT02700815 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01945177 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: narrow band imaging
Description: narrow band imaging
Study NCT01945177 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: white light endoscopy
Description: white light endoscopy
Study NCT02076880 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caloric restriction
Description: Caloric restriction of 1000 kcal per day compared to the usual food intake.~* usual breakfast of the patient (possibly limited in quantity)~* midday and evening meals from mixed and dehydrated meals, soups with protein and dairy desserts sweetened
Study NCT02076880 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No caloric restriction
Description: No change in eating habits to patients in this arm
Study NCT03867981 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based weight loss program
Description: 12-month, Internet-based weight loss/maintenance program.
Study NCT03867981 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet-based weight loss program
Description: 12-month, Internet-based weight loss/maintenance program.
Study NCT03867981 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief phone coaching
Description: Some individuals will receive 3 weeks of phone coaching. Coaching calls will occur 1x/week, starting at week 5. Once coaching calls are completed, the participant will not have any other contact with their coach.
Study NCT03867981 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extended phone coaching
Description: Some individuals will receive 12 weeks of phone coaching. Coaching calls will occur 1x/week, starting at week 5. Once coaching calls are completed, the participant will not have any other contact with their coach.
Study NCT01850550 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight loss Groups
Description: The intervention will consist of 12 weekly one-hour weight loss sessions led by successful volunteer peers. Participants are provided with a modified version of the Diabetes Prevention Program manual and are mentored by peer leaders at weight loss sessions.
Study NCT00926276 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fundoplication
Description: Fundoplication
Study NCT03520374 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Ultrasonography
Description: Ultrasonography use for the evaluation of gastric contents
Study NCT05104164 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-myofascial release
Description: At home, the patients performed a daily session, lasting 15 minutes each, over 8 weeks. Patients accessed an ad hoc mobile application designed by the Hemophilia Physiotherapy research group (He-Foam®). This app, accessible from any smartphone, made it possible to watch the videos with all the exercises included in the intervention. The seven exercises under the specific protocol for patients with hemophilic arthropathy were: Self-release of the plantar region of the foot with a foam ball; Release of the posterior region of the leg with the foam roller; Release of the anterior leg region with a foam roller; Release of the hamstrings region with a foam roller; Release of adductor muscles with a foam ball; Release of abductor muscles with a foam roller; Release of pelvic trochanteric muscles with a foam roller
Study NCT02154490 — intervention group
Intervention type: DRUG
Intervention: Docetaxel
Description: Given IV
Study NCT02154490 — intervention group
Intervention type: BIOLOGICAL
Intervention: Durvalumab
Description: Given IV
Study NCT02154490 — intervention group
Intervention type: DRUG
Intervention: Erlotinib Hydrochloride
Description: Given PO
Study NCT02154490 — intervention group
Intervention type: DRUG
Intervention: FGFR Inhibitor AZD4547
Description: Given PO
Study NCT02154490 — intervention group
Intervention type: BIOLOGICAL
Intervention: Ipilimumab
Description: Given IV
Study NCT02154490 — intervention group
Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03371407 — intervention group
Intervention type: OTHER
Intervention: Assessment of behavioral performance and the electrophysiological (EEG) activity in PD patients during the early and more advanced stages of the pathology
Description: Assessment of behavioral performance and the electrophysiological (EEG) activity in PD patients during the early and more advanced stages of the pathology, using an instrumentation, called the Kinarm, which assess objectively sensory, motor and cognitive functions
Study NCT03893240 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Neutralizing Antibody to SPK-3006 capsid
Description: Collected during a single study visit to establish the occurrence of neutralizing antibodies to SPK-3006 capsid in participants with LOPD on an enzyme replacement regimen.
Study NCT02101801 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: vegetables from fresh or recycled water
Study NCT02101801 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: vegetables from fresh or recycled water
Study NCT02101801 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: receives vegetables from fresh water or recycled waste water farms
Study NCT02101801 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: receives vegetables from fresh water or recycled waste water farms
Study NCT03659903 — intervention group
Intervention type: PROCEDURE
Intervention: pancreaticoduodenectomy
Description: pancreaticoduodenectomy
Study NCT04195438 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: CO Testing Pre/Post Hepatic Resection
Description: Monitor CO in exhaled air of patients before liver resection, at 4 hours and 24 hours after PH
Study NCT04195438 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: ABG Testing Pre/Post Hepatic Resection
Description: Monitor carboxyhemoglobin(COHb) in the arterial blood gas of patients before liver resection at 4 hours and 24 hours after PH
Study NCT04195438 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: CT Evaluations
Description: Analyze the relationship between CO production and the extent of hepatic resection assessed by computed scans liver volumetric study at one and three months after PH, size and weight of the resected specimen and operative report
Study NCT04449393 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Emdogain® FL
Description: Emdogain® FL is an enamel matrix derivative intended for subgingival and topical application in conjunction with scaling and root planing procedures to provide regeneration of tooth support lost due to periodontal disease. Emdogain® FL has been shown to be effective in residual pockets with probing depths from 5mm to 9mm with no furcation involvement in patients with adequate plaque control. Emdogain® FL has also been shown to enhance the early healing of periodontal soft tissue wounds resulting from the instrumentation of periodontal pockets.
Study NCT04449393 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Scaling and root planing
Description: Scaling and root planing procedures as part of non-surgical periodontal therapy involves mechanical removal of dental plaque and calculus using curettes and sonic scalers.
Study NCT00929773 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Erchonia PL2000 Laser
Description: Low level laser light therapy device that emits 1 mW of red (635 nm wavelength) light. It is a hand-held device that uses rechargeable batteries or a separate power adapter.
Study NCT00929773 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo laser
Description: Inactive laser light.
Study NCT02154490 — intervention group
Intervention type: BIOLOGICAL
Intervention: Nivolumab
Description: Given IV
Study NCT02154490 — intervention group
Intervention type: DRUG
Intervention: Palbociclib
Description: Given PO
Study NCT02154490 — intervention group
Intervention type: OTHER
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02154490 — intervention group
Intervention type: BIOLOGICAL
Intervention: Rilotumumab
Description: Given IV
Study NCT02154490 — intervention group
Intervention type: DRUG
Intervention: Talazoparib
Description: Given PO
Study NCT02154490 — intervention group
Intervention type: DRUG
Intervention: Taselisib
Description: Given PO
Study NCT04275271 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational intervention
Description: Skill centered Protocol Training based on IMB model
Study NCT04172415 — intervention group
Intervention type: OTHER
Intervention: Retrospective cohort
Description: Chart Review
Study NCT00570505 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LAP-BAND System
Description: Reduction of food intake due to creation of smaller stomach pouch
Study NCT02203032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: 45 mg or 90 mg given by subcutaneous injection at Weeks 0 and 4 for all participants. Participants with an IGA score of 0 or 1 at Week 16 will also receive ustekinumab every 12 weeks (q12w) from Week 16 to Week 40.
Study NCT01382303 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentoxifylline
Description: Pentoxifylline 400mg three times a day
Study NCT01382303 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo tablet three times a day
Study NCT05837403 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet rich plasma injection
Description: venous blood drown from the patient, centrifugation and separation of platelet rich plasma, injection under fissure and edges base.
Study NCT05837403 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitroglycerin ointment
Description: application of the ointment twice daily
Study NCT05837403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin ointment
Description: application of the ointment twice daily
Study NCT02313727 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pamidronate
Description: intravenous infusion of pamidronate 60 mg
Study NCT02313727 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (NaCl 0.9%)
Description: intravenous infusion of NaCl 0.9% 500 ml
Study NCT03164317 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intervention
Description: A trained nurse care coordinator enabled with a electronic decision support system placed at the CHCs to share the task of management of hypertension.
Study NCT03164317 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: No NCC or EDSS will be placed in the CHCs. Doctors working in the CHCs will be given training (one day) on evidence based management of hypertension
Study NCT03202355 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fixed Appliance Orthodontic Treatment
Description: Patients receive fixed appliance orthodontic treatment by the qualified Principal Investigator (PI). Treatment and follow-up appointments per the traditional practices of the PI and dental office.
Study NCT03202355 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OrthoPulse™
Description: Patients carry out daily OrthoPulse™ treatments at home.
Study NCT00831610 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bariatric surgery (Roux-en-Y Gastric Bypass) + Post-bariatric abdominoplasty.
Description: Surgical removal of the exceeding skin and adiposity of the abdominal wall by one midline vertical fuse and one supra-pubic horizontal fuse. Skin suture without flap undermining and with low tension.
Study NCT00831610 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Roux-en-Y gastric bypass (bariatric surgery) + Post-bariatric abdominoplasty (without flap undermining)
Description: Bariatric surgery Plastic surgery Abdominoplasty
Study NCT00996294 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biliopancreatic diversion, gastric bypass
Description: biliopancreatic diversion consists of a distal gastrectomy with a long Roux-en-Y reconstruction, where the enteroenterostomy is placed 50 cm proximal to the ileocecal valve gastric bypass consists of creating a small proximal gastric pouch by division of the upper stomach, with reconstruction of the GI continuity by means of a Roux-en-Y loop
Study NCT03858335 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Constraint-induced movement therapy
Description: The constraint-induced movement therapy (CIMT) program requires children to wear forearm splint on the unaffected arm 24 hours for 3 weeks. The program consists of 5 sessions per week for 3 weeks.
Study NCT02671890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Study NCT02671890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disulfiram
Description: Given PO
Study NCT02671890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study NCT02671890 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00792662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: Subject will receive 5mg BID for the first two weeks then 10mg BID until week 16 of the study.
Study NCT00792662 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Standard inactive pill.
Study NCT04068181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talimogene laherparepvec
Description: Intralesional injection into injectable cutaneous, subcutaneous and nodal legions.
Study NCT04068181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous (IV) infusion.
Study NCT03519971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab IV (intravenous infusion)
Study NCT03519971 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo IV (intravenous infusion)
Study NCT03519971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin/ Etoposide
Description: Cisplatin/ Etoposide, as per standard of care
Study NCT03519971 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin/ Etoposide
Description: Cisplatin/ Etoposide, as per standard of care
Study NCT03519971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin/ Paclitaxel
Description: Carboplatin /Paclitaxel, as per standard of care
Study NCT03519971 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin/ Paclitaxel
Description: Carboplatin /Paclitaxel, as per standard of care
Study NCT03519971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed/ Cisplatin
Description: Pemetrexed / Cisplatin, as per standard of care
Study NCT03519971 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pemetrexed/ Cisplatin
Description: Pemetrexed / Cisplatin, as per standard of care
Study NCT03519971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed/ Carboplatin
Description: Pemetrexed / Carboplatin , as per standard of care
Study NCT03519971 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pemetrexed/ Carboplatin
Description: Pemetrexed / Carboplatin , as per standard of care
Study NCT03519971 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: 5 fractions/ week for \~6 weeks (±3 days) (Total 60 Gy)
Study NCT03519971 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Radiation
Description: 5 fractions/ week for \~6 weeks (±3 days) (Total 60 Gy)
Study NCT01208662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: oral administration
Study NCT01208662 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: oral administration
Study NCT01208662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: intravenous or, following protocol amendment, subcutaneous administration
Study NCT02203032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: 100 mg given by subcutaneous injection at Weeks 16 and 20 and every 8 weeks (q8w) thereafter through Week 44.
Study NCT01208662 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: intravenous or, following protocol amendment, subcutaneous administration
Study NCT02203032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for ustekinumab
Description: Subcutaneous injection at Weeks 16, 28, and 40 to maintain the blind for participants randomized to treatment with guselkumab.
Study NCT02203032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for guselkumab
Description: Subcutaneous injection at Weeks 16 and 20 and q8w thereafter through Week 44 to maintain the blind for participants randomized to treatment with ustekinumab.
Study NCT01208662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: oral administration~Dose of 20 mg/day for first 3 cycles. Dose of 10 mg/day for remaining cycles.
Study NCT01208662 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: oral administration~Dose of 20 mg/day for first 3 cycles. Dose of 10 mg/day for remaining cycles.
Study NCT01208662 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous Stem Cell Transplant
Description: Autologous refers to stem cells that are harvested from the participant to be a source of new blood cells after high-dose chemotherapy with melphalan.
Study NCT03569748 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IQOS
Description: IQOS USE FOR 12 WEEKS
Study NCT02154490 — intervention group
Intervention type: BIOLOGICAL
Intervention: Tremelimumab
Description: Given IV
Study NCT02194205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COMBIVENT HFA
Study NCT02194205 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo HFA
Study NCT02194205 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: COMBIVENT CFC
Study NCT02194205 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo CFC
Study NCT03590236 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Graded exposure therapy
Description: Patients included in this group received graded exposure therapy consisting on counselling, a graded activity through postural exercises and individual training focused on 5 activities selected by the patients. The treatment will include 5 sessions added to the 12 sessions of physiotherapy.
Study NCT03590236 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: Physiotherapy intervention will include soft tissue mobilizations and myofascial release combined with deep-pressure massage to decrease trigger point-related pain and tension. In addition joint mobilization and muscle energy techniques will be included.
Study NCT00180414 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CRT devices with ventricular rate regulation [VRR] (CE labeled)
Study NCT00180414 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRT devices with ventricular rate regulation [VRR] (CE labeled)